San Antonio 2013

2»

Comments

  • Moderators
    Moderators Member Posts: 25,912
    edited December 2013


    CP418, we're not seeing any issues with the link. Can you give it another shot and let us know?

    · Share on FacebookShare on Twitter
  • cp418
    cp418 Member Posts: 7,079
    edited December 2013

    Hmmm...... I can open your other link in the Podcasts forum but this one still gives me a website security certificate error.

    · Share on FacebookShare on Twitter
  • Anonymous
    Anonymous Member Posts: 1,376
    edited December 2013

    Listened to the Podcast.  Excellent information.  Thanks moderators!

    · Share on FacebookShare on Twitter
  • bevin
    bevin Member Posts: 1,902
    edited December 2013


    I'm not a statistician, and have a question on the verbiage.. it reads LOWER disease free survival than expected... doesn't this mean more disease occured than expected. ? If it said HIGHER disease free survival , then more people survived than expected.? Let me know.

    · Share on FacebookShare on Twitter
  • farmerlucy
    farmerlucy Member Posts: 3,985
    edited December 2013


    I thought the podcasts were excellent! Very informative and hopeful. Thanks so much!

    · Share on FacebookShare on Twitter
  • Moderators
    Moderators Member Posts: 25,912
    edited December 2013


    In the December 13, 2013 edition of our podcast coverage from the 2013 San Antonio Breast Cancer Symposium, we bring you the latest information from these areas of breast cancer research:

    • post-treatment psychosocial and physical issues
    • updates on chemotherapy in high-risk women, early and metastatic breast cancers, triple-negative breast cancers, and in women with high numbers of circulating tumor cells
    • a new design for clinical trials that may allow drugs to become available sooner
    • breast cancer incidence in women using hormonal treatments for infertility
    • a presentation on what women know about risk reduction versus how they put this knowledge into practice, from Breastcancer.org founder and president Marisa Weiss, M.D.


    Running time: 24:18

    · Share on FacebookShare on Twitter
  • bevin
    bevin Member Posts: 1,902
    edited December 2013

    HI KayB

    It was in the SOFT trial : Herre is the copied text: RESULTS: TEXT and SOFT successfully met their enrollment goals in 2011. The 5738 enrolled women had lower-risk disease and lower observed disease-free survival (DFS) event rates than anticipated. Consequently, 7 and 13 additional years of follow-up for TEXT and SOFT, respectively, were required to reach the targeted DFS events (median follow-up about 10.5 and 15 years). To provide timely answers, protocol amendments in 2011 specified analyses based on chronological time and median follow-up. To assess the AI question, exemestane + OFS versus tamoxifen + OFS, a combined analysis of TEXT and SOFT became the primary analysis (n = 4717). The OFS question became the primary analysis from SOFT, assessing the unique comparison of tamoxifen + OFS versus tamoxifen alone (n = 2045). The first reports are anticipated in mid- and late-2014

    Let me know your thoughts...

    Bevin

    · Share on FacebookShare on Twitter
  • voraciousreader
    voraciousreader Member Posts: 7,496
    edited December 2013

    http://www.thebreastonline.com/article/S0960-9776(...

    · Share on FacebookShare on Twitter
  • voraciousreader
    voraciousreader Member Posts: 7,496
    edited December 2013

    Here's an email that I received from my contact at Dana Farber who is collecting the information regarding SOFT and TEXT:

    "Dear  ____,
    Thank you for your note. The first trial results are anticipated to report in 2014, and will be reported at one of the large conferences such as ASCO or SABCS. You are correct that we've been observing fewer recurrences than expected--which as you say is the good news--and for that reason, we will combine TEXT and SOFT together to answer the question of the role of aromatase inhibitor with ovarian function suppression vs. tamoxifen with OFS; this is done so that we learn the answer the question now rather than waiting for many more years.
    Kind regards,
    Meredith"

    · Share on FacebookShare on Twitter
  • voraciousreader
    voraciousreader Member Posts: 7,496
    edited December 2013


    Here's what our fellow sister on the Stage 1 Grade 1 and Premenopausal thread said about the latest info regarding SOFT and TEXT:

    "Nov 17, 2013 05:33pm Annicemd wrote:

    Thanks so much to VR for keeping us up to date with the latest info on this exciting research.

    My interpretation of the preliminary info is that there are fewer recurrences than predicted in all groups and this is a big study - the study investigators would have done a power calculation at the outset of the study predicting how many recurrences would be expected based on historic recurrence rates at that time. Tentatively I think that the fact that there are fewer recurrences at this stage is good news. It illustrates that survival rates are improving and recurrence rates are falling with improved conventional treatments hence having to extend the data collection. So regardless of whether those of us on this thread have gone for aggressive additional hormone treatment or not it is likely that we are all likely to have better survival than the stats (that we are all used to stressing over) predict.

    As far as I am concerned it looks like good news for all!

    Here's what 

    Annice"

    · Share on FacebookShare on Twitter
  • cp418
    cp418 Member Posts: 7,079
    edited December 2013

    kayb - hearing your sister is 24yr survivor is fantastic!!  Smile

    · Share on FacebookShare on Twitter
  • Sherryc
    Sherryc Member Posts: 5,938
    edited December 2013

    Thanks for the updates

    · Share on FacebookShare on Twitter
  • cp418
    cp418 Member Posts: 7,079
    edited December 2013

    http://www.obgynnews.com/single-view/no-overall-benefit-seen-with-bisphosphonate-treatment-in-chemoresistant-breast-cancer/08a4534db9c713ceccc3c780fe258bcc.html

    No overall benefit seen with bisphosphonate treatment in chemoresistant breast cancer

    · Share on FacebookShare on Twitter

Categories